Cargando…
Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation in the Emergency Department: The SPECTRUM Study
INTRODUCTION: Intravenous vernakalant is a therapeutic option for symptomatic, recent-onset atrial fibrillation (AF). This secondary analysis from the large SPECTRUM study assessed the safety and effectiveness of vernakalant when used in the emergency department setting (ED group) or in an inpatient...
Autores principales: | Bager, Johan-Emil, Martín, Alfonso, Carbajosa Dalmau, José, Simon, Alexander, Merino, José L., Ritz, Beate, Hartikainen, Juha E.K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808723/ https://www.ncbi.nlm.nih.gov/pubmed/36282074 http://dx.doi.org/10.1159/000526831 |
Ejemplares similares
-
Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study
por: Lévy, Samuel, et al.
Publicado: (2020) -
Feasibility of Patient-Managed ECG Recordings to Detect the Time of Atrial Fibrillation Recurrence after Electrical Cardioversion: Results from the PRE-ELECTRIC Study
por: Andersen, Elizabeth Lyster, et al.
Publicado: (2023) -
Differentiation of Atrial Fibrillation and Atrial Fibrillation-Associated Ischemic Stroke Based on Serum Exosome miRNA-Seq
por: Xie, Yun, et al.
Publicado: (2023) -
Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update
por: Tsuji, Yukiomi, et al.
Publicado: (2013) -
Body Weight Counts—Cardioversion with Vernakalant or Ibutilide at the Emergency Department
por: Lindmayr, Teresa, et al.
Publicado: (2022)